Toyohara Keiko, Fukuhara Hitoo, Yoshimoto Jun, Ozaki Noriyasu, Nakamura Yoshihide
Japanese Red Cross Society, Wakayama Medical Center, Wakayama, Japan.
Pediatr Cardiol. 2011 Jan;32(1):40-6. doi: 10.1007/s00246-010-9809-3. Epub 2010 Oct 10.
Ectopic atrial tachycardia (EAT) often resists medical therapy, making radiofrequency catheter ablation (RFCA) the preferred treatment. This study reviewed the records of 35 patients who underwent electrophysiologic studies (EPS) and 39 RFCA procedures for EAT during a 10-year period. Of the 35 patients, 10 (28%) presented with decreased ventricular function and tachycardia-induced cardiomyopathy (TIC). The EAT originated on the right atrial side in 19 patients (54%) and on the left atrial side in the remaining 16 patients (46%). The right atrial sites included the right atrial appendage (RAA) (n = 9, 25%), the tricuspid annulus (n = 7, 20%), and the crista terminalis (n = 3). The left atrial sites included the left atrial appendage (LAA) (n = 6, 17%), the pulmonary veins (n = 5, 14%), the mitral annulus (n = 3), and the posterior wall of the left atrium (n = 2). The mechanism of all EAT probably is automaticity. All EATs could be abolished using RFCA. Follow-up data were available for all patients 2 to 8 years after RFCA. All 35 patients remained recurrence free, and ventricular function improved for all 10 patients with TIC. The origin of EAT in children differed from its origin in adults. The authors conclude that RFCA is a safe and effective treatment option for children with refractory EAT and should be considered early in the course of their illness.
异位性房性心动过速(EAT)常常对药物治疗耐药,这使得射频导管消融术(RFCA)成为首选治疗方法。本研究回顾了35例在10年期间接受电生理检查(EPS)以及针对EAT进行39次RFCA手术的患者记录。在这35例患者中,10例(28%)出现心室功能减退和心动过速性心肌病(TIC)。EAT起源于右心房侧的有19例患者(54%),起源于左心房侧的有其余16例患者(46%)。右心房部位包括右心耳(RAA)(n = 9,25%)、三尖瓣环(n = 7,20%)和界嵴(n = 3)。左心房部位包括左心耳(LAA)(n = 6,17%)、肺静脉(n = 5,14%)、二尖瓣环(n = 3)和左心房后壁(n = 2)。所有EAT的机制可能是自律性。所有EAT均可通过RFCA消除。所有患者在RFCA术后2至8年都有随访数据。所有35例患者均无复发,且10例患有TIC的患者心室功能均有改善。儿童EAT的起源与成人不同。作者得出结论,RFCA对于难治性EAT患儿是一种安全有效的治疗选择,应在病程早期予以考虑。